Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival analysis from the phase II IMvigor210 study (cohort 1) Meeting Abstract
| Authors: | Rosenberg, J. E.; Galsky, M. D.; Balar, A. V.; Loriot, Y.; Necchi, A.; Hoffman-Censits, J.; Srinivas, S.; Drakaki, A.; Javery, A.; Nelson, B.; Huang, H. X.; Shen, X.; van der Heijden, M. S. |
| Abstract Title: | Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival analysis from the phase II IMvigor210 study (cohort 1) |
| Meeting Title: | ESMO Congress 2021 |
| Journal Title: | Annals of Oncology |
| Volume: | 32 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2021 Sep 16-21 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2021-09-01 |
| Start Page: | S711 |
| End Page: | S712 |
| Language: | English |
| ACCESSION: | WOS:000700527701165 |
| DOI: | 10.1016/j.annonc.2021.08.095 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract #669P -- Source: Wos |
